Search Results for "Http Dx Doi Org 10 1002 Adma 201104290"

12:27 EDT 31st October 2014 | BioPortfolio

Matching Channels

Freiberg Infraction

Freiberg's disease is an osteochondrosis of the metatarsal head, most commonly occurring in young athletes older than 12 years who perform on their toes in either sprinting or jumping activities...

Pediculosis - louse (lice) treatment

   To view our most recent articles on Lice Treatment please go to: http://www.bioportfolio.com/news/article/987636/Pediculosis-Louse-Lice-Treatment.html    

Pediculosis - louse (lice) infestation

   To view our most recent article on Lice Infestation please go to: http://www.bioportfolio.com/news/article/987568/Pediculosis-Louse-Lice-Infestation.html 

Pediculosis - louse (lice) diagnosis

   To view our most recent articals on Lice Diagnosis please view: http://www.bioportfolio.com/news/article/987588/Pediculosis-Louse-Lice-Diagnosis.html

G-protein-coupled receptors (GPCRs)

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers th...

Matching News

Biotechs With Insider Buying

By Intrepid Investor:ADMA Biologicals' (OTCQB:ADMA) insider Adam Grossman bought 2,100 shares on August 13. ADMA is a $91M market cap company that collects blood, separates it into its components, and...

Esperion jumps on Phase IIb ETC-1002 results

Esperion Therapeutics Inc. (NASDAQ:ESPR) said both doses of its ETC-1002 met the primary endpoint compared to ezetimibe in a Phase IIb study to treat patients with hypercholesterolemia, with or withou...

Esperion begins dosing for ETC-1002 Phase II trial in hypercholesterolemia, hypertension patients

US-based biopharmaceutical firm Esperion Therapeutics has dosed the first patient in its Phase II clinical trial of ETC-1002 to treat patients with hypercholesterolemia and hypertension, ETC-1002-014.

Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia

- ETC-1002-008 study meets primary endpoint - - LDL-cholesterol lowering significantly greater with ETC-1002 than ezetimibe - - ETC-1002 appears to be saf...

Esperion outlines more milestones

Esperion Therapeutics Inc. (NASDAQ:ESPR) added $2.58 (11%) to $27 on Thursday in the wake of positive Phase IIb results for the company's cholesterol-lowering molecule ETC-1002 in patients with hyperc...

QPI-1002 misses in graft function Phase II

The Quark Pharmaceuticals Inc. subsidiary of SBI Biotech Co. Ltd. (Tokyo, Japan) said a single IV dose of QPI-1002 missed the primary endpoint vs. placebo in the Phase II portion of the Phase I/II QRK...

ADMA Biologics to Present at 9th Annual JMP Securities Healthcare Conference on June 24

ADMA Biologics, Inc. (OTCQB: ADMA), a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment an...

Quark reports favorable results from Phase II clinical trial evaluating investigational siRNA QPI-1002

Quark Pharmaceuticals has reported data from a randomized, double-blinded, placebo-controlled multicenter Phase II clinical trial (QRK.006B; ClinicalTrials.gov identifier: NCT00802347) of QPI-1002, a ...

Matching PubMed Articles

Rejoinder.

This is the reply to the discussion of the two companion articles on the theory and application of "probability estimation with machine learning methods for dichotomous and multicategory outcome" by K...

The Endothelial ADMA/NO Pathway in Hypoxia-Related Chronic Respiratory Diseases.

Since its discovery, many adhere to the view that asymmetric dimethylarginine (ADMA), as an inhibitor of the synthesis of nitric oxide (NO), contributes to the pathogenesis of various diseases. Partic...

Dimethylarginines: endogenous inhibitors of nitric oxide synthesis in children with falciparum malaria.

Background. Nitric oxide (NO) bioavailability is impaired in children and adults with severe falciparum malaria (SM). Asymmetric-dimethylarginine (ADMA) limits NO production by inhibiting NO synthas...

Modeling the Time-Varying Subjective Quality of HTTP Video Streams With Rate Adaptations.

Newly developed hypertext transfer protocol (HTTP)-based video streaming technologies enable flexible rate-adaptation under varying channel conditions. Accurately predicting the users' quality of expe...

Serum reference intervals of homoarginine, ADMA, and SDMA in the Study of Health in Pomerania.

Abstract Background: Low circulating homoarginine as well as high levels of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) have been associated with impaired cardiovascular (...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement